| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.87.3.831 |
| P698 | PubMed publication ID | 8443903 |
| P2093 | author name string | Weintraub WS | |
| Morris DC | |||
| King SB 3rd | |||
| Douglas JS Jr | |||
| Liberman HA | |||
| Cohen CL | |||
| Ghazzal ZM | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | angiography | Q468414 |
| angioplasty | Q539795 | ||
| P304 | page(s) | 831-840 | |
| P577 | publication date | 1993-03-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Long-term clinical follow-up in patients with angiographic restudy after successful angioplasty. | |
| P478 | volume | 87 |
| Q33726389 | A comparison of cardiovascular procedure use between the United States and Canada. |
| Q33867830 | Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation |
| Q33504164 | Abciximab. An updated review of its use in ischaemic heart disease |
| Q40457712 | Antithrombotic and thrombolytic therapy in patients undergoing coronary artery interventions: A review |
| Q51094146 | Asymptomatic restenosis: should we (re)intervene? An unresolved dilemma. |
| Q71774924 | Atherosclerosis and restenosis: reflections on the Lovastatin Restenosis Trial and Scandinavian Simvastatin Survival Study |
| Q77707997 | Clinical and angiographic determinants of adverse cardiac events in patients with stent restenosis |
| Q44435381 | Coronary artery disease in HIV infected patients |
| Q51179501 | Cost effectiveness of the sirolimus-eluting stent in high-risk patients in Canada: an analysis from the C-SIRIUS trial. |
| Q51520186 | Do drug-eluting stents mark the end of coronary artery bypass surgery? |
| Q51484880 | Dollars and stents: the economics of drug-eluting stents. |
| Q36812894 | Drug eluting stents for ST-elevation myocardial infarction: risk and benefit |
| Q35753833 | Drug-eluting stent task force: final report and recommendations of the working committees on cost-effectiveness/economics, access to care, and medicolegal issues. |
| Q50944371 | Drug-eluting stent thrombosis vs bare metal stent restenosis: finding the lesser of two evils. |
| Q36314909 | Drug-eluting stents: from evidence to policy |
| Q36884413 | Drug-eluting stents: trading restenosis for thrombosis? |
| Q35366286 | Effectiveness and cost effectiveness of single bolus treatment with abciximab (Reo Pro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patients |
| Q35072177 | Exercise stress testing, myocardial perfusion imaging and stress echocardiography for detecting restenosis after successful percutaneous transluminal coronary angioplasty: a review of performance. |
| Q35987046 | From balloon angioplasty to drug-eluting stents: revolution or evolution? |
| Q74660460 | Long-term angiographic prognosis of lesions dilated by coronary angioplasty |
| Q30305538 | Management of Acute Ischemic Coronary Syndromes: The Present and Future |
| Q40486896 | Mechanisms of restenosis |
| Q35915178 | Molecular atherectomy for restenosis |
| Q77220467 | Outcome of target sites escaping high-grade (>70%) restenosis after percutaneous transluminal coronary angioplasty |
| Q35952194 | Plaque sealing by coronary angioplasty |
| Q36893705 | Prospective, randomized, multicenter comparison of laser-facilitated balloon angioplasty versus stand-alone balloon angioplasty in patients with obstructive coronary artery disease. The Laser Angioplasty Versus Angioplasty (LAVA) Trial Investigators |
| Q71870074 | Rapid angiographic progression of “target” and “nontarget” stenoses in patients awaiting coronary angioplasty |
| Q50946296 | Restenosis or rapid progression in non-dilated sites are not predictors of late spontaneous coronary events. |
| Q71977985 | Restenosis: The “hole” truth? |
| Q74194589 | Risk stratification after successful coronary revascularization: the lack of a role for routine exercise testing |
| Q72792796 | ST-segment computerized monitoring before and after angioplasty: clinical correlation with recurrent angina during the short-term follow-up |
| Q37139276 | Safety of drug-eluting stents |
| Q46735847 | Spontaneous regression of restenosis: An angiographic study |
| Q36540735 | Ten-year mortality risk of patients undergoing elective PCI: long-term follow-up of the GENetic Determinants of Restenosis (GENDER) study : No increased mortality risk by restenosis, only by coronary artery disease itself |
| Q35987013 | The drug-eluting stent information gap. |
| Q45004977 | The national registry EVASTENT: cost-effectiveness analysis of the sirolimus active stent in diabetic and non-diabetic patients |
| Q27025740 | The perils of surrogate endpoints |
| Q74251431 | Usefulness of the substitution of nonangiographic end points (death, acute myocardial infarction, coronary bypass and/or repeat angioplasty) for follow-up coronary angiography in evaluating the success of coronary angioplasty in patients with angina |
Search more.